Disclosure! These peptides have not been evaluated by the FDA. These peptides are not a form of medication and are for research purposes only. Purchasing research peptides for personal use is illegal.
Cargrilintide Cas # 1415456-99-3
Cagrilintide is a long-acting analogue of amylin. It is being tested to treat obesity and type 2 diabetes by itself and in combination with semaglutide as cagrilintide/semaglutide
– Metabolic enhancementCagrilintide is a novel peptide that activates amylin and calcitonin receptors. It works by suppressing appetite, slowing gastric emptying after meals, and inhibiting glucagon secretion outside of hypoglycemic states. This research chemical is being studied for various applications, including:
– Weight loss
– Type 2 diabetes
– Metabolic enhancement
To fully leverage the research potential of cagrilintide, it is crucial for researchers to stay informed about the latest developments. This comprehensive guide aims to equip scientists with essential insights for studying and experimenting with cagrilintide. Additionally, we provide guidance on sourcing high-quality, research-grade cagrilintide to ensure that studies uphold the highest standards of scientific rigor and accuracy.
*. This information, including any referenced scientific or clinical research, is available for educational purposes only. Furthermore, any published information related to the dosing and administration of reference materials is provided strictly for reference and shall not encourage self-administration or any human use of the mentioned materials. Biotechlabzsupply.com strives to ensure compliance with national and international clinical trial information standards and is committed to the timely disclosure of the design and results of all interventional clinical studies for innovative treatments, whether publicly available or anticipated. However, research findings are not considered conclusive. Peptides.org makes no claims that any referenced products can cure, treat, or prevent any conditions, including those mentioned on its website or in print materials.
What is Cagrilintide?
Cagrilintide, also known as AM833, NNC0174-0833 and GLXC01, is a synthetic peptide that acts as a dual amyl and calciton receptor agonist (DAC) based on human amylin. Researchers with these hormones should note that:
-ylin, or islet amyloid polypeptide, is 37-amino-acid peptide hormone secreted by pancreas alongside insulin. It reduces gluc levels after meals, slows gastric emptying, and feelings.
– Calciton is a naturally hormone produced by the thyroid gland that regulates calcium levels in the body by promoting calcium in bones. Research also suggests may help lower blood glucose levels in diabetic conditions.
Developed by Novo Nordisk, Cagrilintide designed to mimic the natural effects of amylin on the amylin calcitonin receptors regulate blood sugar, digestive motility, and appetite. This peptide enhances receptor activity compared to naturally occurring amylin incorporating specific amino acid. features the attachment of a C-20 fatty diacid via an α-glutamyl, prolonging its half-life to up to 7. days, allowing for oncely subcutaneous injections.
The primary research focus Cilintide studies is weight management and the treatment of obesity and related, such as type 2 diabetes (T2D). Although Cagrilintide has not yet received approval from the U.S. and Drug AdministrationFDA), it is currently undergoing phase 3 clinical trials in combination with semagide the trade name CriSema. Semaglut, which has already been approved by FDA is administered via oncely injections aimed at gly control and reducing the risk of cardiovascular events in individuals T2D. It is also approved for managing overweight and obesity in individuals 12 years and older. Semaglutide has a prolonged half-life exceeding one week and mimics the action of the incretin hormone glucagon-like peptide- (GLP-1).
Cagrilintide is available for research to qualified professionalsCagrilintide: Athrough in Obesity Research
Cagrilintide acts as a non-selective agon forylin receptors (AMYRs) and calcin receptors (CTRs). It aims to in obesity management by reducing food intake and promoting weight loss in a-dependent manner. The primary mechanism action for cagrilintide its interaction with AMYRs and CTR, which are abundantly expressed in the and play critical role in regulating satiety. By activating these receptors, cagrilintide effectively signals a sense of fullness to the brain’s homeostatic centers, the nucleus tractus solitarius (NTS) and area postrema (AP) located in brainstem. This action decrease the patients’ desire eat and lower their overall food intake, leading to weight lossAdditionally, cagrilintide slows gastric emptying and suppresses glucagon secretion. These effects contribute to extended periods of satiety after meals and more stable glucose levels, both of which are advantageous for weight management and metabolic health. Notably, the effects on gastric emptying glucagon secretion occur postprandially, when blood sugar levels are elevated. This means that amylin analogs like cagrilintide do not interfere with glucagon production or normal gastric emptying during periods of normal blood sugar levels. Consequently, this peptide can aid in lowering blood sugar without posing a risk of hypoglycemia.
Cilintide was developed in the early2010 by the Danish pharmaceutical company Novo Nordisk, primarily targeting conditions such as obesity and type 2 diabetes (TD). Below we have outlined of the most notable research applications of cagrilintide based on the available clinical trials.
Cagrilintide for Management Research
Research regarding the potential weight loss of cagrilintide in people with obesity (but without T2D) includes notable
These results indicate that 2.4 mg of weekly cagrilintide is more effective for weight reduction than 2.4 mg of weekly semaglutide. Additionally, cagrilintide significantly enhances the weight loss and antidiabetic properties of semaglutide.
Ongoing Research into T2D and Obesity
Novo Nordisk has initiated the ambitious REDEFINE and REIMAGINE phase 3 clinical programs to investigate the efficacy of combining cagrilintide and semaglutide (CagriSema) for weight management and Type 2 diabetes treatment across diverse patient populations.
The REDEFINE program focuses primarily on assessing the weight loss potential of the cagrilintide plus semaglutide combination in individuals with and without diabetes. This program includes six trials, five of which are detailed below:
: A 68-week trial involving 3,400 patients, comparing cagrilintide plus semaglutide against monotherapies and placebo, with weight loss as the primary outcome.
: A 68-week trial with 1,200 patients, comparing cagrilintide plus semaglutide against placebo, focusing on weight loss as the primary outcome.
: A large-scale trial involving 7,000 patients, assessing cagrilintide plus semaglutide with a focus on major adverse cardiovascular events as the primary outcome.
-: A 72-week head-to-head trial involving 800 patients, comparing cagrilintide plus semaglutide against tirzepatide, with weight loss as the primary outcome.
: A 68-week trial conducted in East Asia with 330 patients, comparing cagrilintide plus semaglutide against semaglutide 2.4 mg, with weight loss as the primary outcome.
In parallel, Novo Nordisk’s REIMAGINE program specifically targets the management of Type 2 diabetes through the combined use of cagrilintide and semaglutide, encompassing four trials:
: A 40-week trial involving 180 patients with T2D, comparing cagrilintide plus semaglutide against placebo, with HbA1c levels as the primary outcome.
: A 68-week trial with 2,700 patients on metformin (MET) with or without SGLT-2 inhibitors, comparing cagrilintide plus semaglutide against semaglutide, cagrilintide alone, and placebo, with both HbA1c and body weight as primary outcomes.
: A 40-week trial involving 270 patients with T2D on basal insulin with or without MET, assessing cagrilintide plus semaglutide as an add-on therapy compared to placebo, with HbA1c levels as the primary outcome.
: A 68-week head-to-head trial with 1,000 patients on MET with or without SGLT-2 inhibitors, comparing cagrilintide plus semaglutide against tirzepatide, focusing on HbA1c and body weight as primary outcomes.
These comprehensive and large-scale studies aim to establish the efficacy and safety profile of cagrilintide plus semaglutide, potentially positioning it as a key therapeutic option for weight management and diabetes control. Currently, all of these trials are in the recruitment phase, with the first results expected as soon as 2026 or 2027.
Lyophilized powder form, intended solely for laboratory use and not for human consumption.
Submit your review | |
